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ABSTRACT
Purpose: In 75% of ovarian cancer patients the tumor mass is completely 
eradicated by established surgical and cytotoxic treatment; however, the majority of 
the tumors recur within 24 months. Here we investigated the role of circulating tumor 
cells (CTCs) indicating occult tumor load, which remains inaccessible by established 
diagnostics.
Experimental design: Blood was taken at diagnosis (baseline samples, n = 102) 
and six months after completion of adjuvant first-line chemotherapy (follow-up 
samples; n = 78). CTCs were enriched by density gradient centrifugation. A multi-
marker immunostaining was established and further complemented by FISH on CTCs 
and tumor/metastasis tissues using probes for stem-cell like fusion genes MECOM 
and HHLA1.
Results: CTCs were observed in 26.5% baseline and 7.7% follow-up blood samples 
at a mean number of 12.4 and 2.8 CTCs per ml blood, respectively. Baseline CTCs 
indicated a higher risk of death in R0 patients with complete gross resection (univariate: 
HR 2.158, 95% CI 1.111–4.191, p = 0.023; multivariate: HR 2.720, 95% CI 1.340–5.522, 
p = 0.006). At follow-up, the presence of CTCs was associated with response to primary 
treatment as assessed using RECIST criteria. Chromosomal gains at MECOM and HHLA1 
loci suggest that the observed cells were cancer cells and reflect pathophysiological 
decisive chromosomal aberrations of the primary and metastatic tumors.
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Conclusions: Our data suggest that CTCs detected by the multi-marker protein 
panel and/or MECOM/HHLA1 FISH represent minimal residual disease in optimally 
debulked ovarian cancer patients. The role of CTCs cells especially for clinical therapy 
stratification of the patients has to be validated in consecutive larger studies applying 
standardized treatment schemes.
INTRODUCTION
Ovarian cancer has the highest mortality rate of 
all gynecological cancers [1]. The standard of care for 
patients with advanced stage ovarian cancer consists 
of maximal cytoreductive or debulking surgery, and 
followed by a platinum-based adjuvant chemotherapy in 
combination with paclitaxel [2]. Residual disease after 
surgery is one of the most relevant prognostic factors for 
the patients [3]. However, even in optimally debulked 
patients without evidence of macroscopic residual tumor 
mass and/or with complete clinical response to first-line 
chemotherapy (according to the GCIG criteria [4]), the 
disease will recur in about 80% of these patients within 
24 months, with fatal outcome.
Currently, there is a major effort to identify biological 
markers of minimal residual disease (MRD), which remains 
inaccessible by clinically established staging procedures 
and measurement of the serum tumor marker CA-125. 
In this regard, circulating tumor cells (CTCs) have been 
actively investigated in a number of solid tumor types, 
predominantly using the FDA approved CellSearch assay 
(Janssen Diagnostic, USA) [5]. In ovarian cancer, there 
has been growing evidence that CTCs are of prognostic 
relevance as well (reviewed by Romero-Laorden et al. 
[6]). Hematogenous spread has not been deemed a major 
issue for this type of cancer, until Pradeep and colleagues 
showed in a parabiosis mouse model that ovarian cancer 
disseminates to the omentum and subsequently to the 
peritoneum not only due to intraperitoneal “seeding”, but 
also via the hematogenous route [7]. Thus we hypothesized 
that CTCs may serve as indicators for tumor load at any 
time and for treatment response in ovarian cancer as well, 
and that CTCs could be used as surrogate markers of the 
risk of recurrence and metastasis.
The aim of the present study was to investigate the 
prognostic impact of CTCs on the outcome of ovarian cancer 
patients included into the OVCAD study cohort, and whether 
these CTCs could serve as surrogate markers for MRD 
beyond surgery. Initially, the blood samples were processed 
using a combined approach consisting of an immune-
magnetic enrichment of CTCs expressing the epithelial 
cell surface marker epithelial cell adhesion molecule 
(EpCAM) and a subsequent immune-fluorescent staining 
of intracellular cytokeratins (protocol A). In the course of 
the study we developed a more comprehensive protocol for 
the immune-fluorescent multi-marker staining of additional 
targets, namely epithelial growth factor receptor (EGFR), 
human epidermal growth factor receptor 2 (HER2), mucin 1 
(MUC1), as well as EpCAM and cytokeratins (protocol B). 
The blood samples were taken at two time-points: First, 
at primary diagnosis before any therapeutic intervention 
(baseline samples), and second, six months after completion 
of the adjuvant platinum-based chemotherapy (follow-up 
samples). In addition to immune-fluorescent staining of 
CTCs, we performed fluorescence in situ hybridization 
(FISH) in some selected cases to investigate the copy number 
of the stem-cell like fusion genes MECOM/HHLA1 and to 
pinpoint CTCs as cancer cells in case of doubt. 
RESULTS
Patient characteristics
Blood samples were available from 266 of the 275 
OVCAD study patients, comprising 241 samples taken 
at diagnosis, and 134 samples taken six months after 
completion of the primary treatment. The samples were 
processed according to protocol A in the first part of the 
study and to protocol B in the later course (see Figure 1). 
The patients were mainly diagnosed with FIGO stage III 
disease (77.1%), with high grade (72.2%), and serous 
(86.1%) histology. The majority of the patients (68.0%) 
was optimally debulked leaving no macroscopically 
visible tumor mass after surgery (R0); in 18.4% of the 
cases, neo-adjuvant chemotherapy was administered prior 
to surgery. Six months after completion of the adjuvant 
chemotherapy, 74.4% of the patients were classified as 
responders and 24.8% as non-responders according to 
the RECIST criteria. The proportion of FIGO stage IV 
patients was significantly higher in the protocol B than 
in the protocol A baseline samples (30.4% vs. 11.5%; p = 
0.001), as well as the proportion of high grade tumors 
(79.4% vs. 64.7%; p = 0.022). Among the follow-up 
samples processed according to protocol A, we observed 
more R0 patients (82.1% vs 62.8%; p = 0.015) and patients 
having received a neo-adjuvant chemotherapy (26.8% vs. 
12.8%; p = 0.046) than in protocol B follow-up samples. 
The median follow-up time of protocol B patients was 67 
months (interquartile range, 61 to 73 months), with 108 
recurrences and 83 cases of deaths. 
CK+/CD45– CTCs in protocol A 
In total, blood samples from 153 patients were 
processed according protocol A, which combined density 
gradient centrifugation, immune-magnetic isolation of 
EpCAM-positive cells and immune-fluorescent staining of 
cytokeratins. Blood samples taken at both time-points were 
available in 42 cases, whereas just one sample was available 
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in (baseline) and in 14 (follow-up) cases, respectively. 
We observed CK+/CD45– CTCs in 5/139 (3.6%) baseline 
samples and in none of the 56 follow-up blood samples [8] 
(see Figure 1). More than one CK+/CD45– CTC was found 
in just a single baseline blood sample. The primary tumors 
of the five CTC-positive patients were classified as FIGO 
stage III (n = 4) and IV (n = 1). Due to the low number 
of CTC-positive samples, we did not perform any further 
statistical evaluation of the data. 
Additional CTC markers for protocol B 
Based on an extensive literature research we selected 
EpCAM, EGFR, HER2, and MUC1 to complement 
the immune-fluorescent detection of CTCs based on 
cytokeratins alone in protocol A. To find out whether 
these markers were indeed appropriate to detect CTCs in 
our cohort, we evaluated the microarray gene expression 
data from the respective primary tumor tissues. These 
data, which were available from 93 of the 137 patients 
whose blood samples had not been processed according 
protocol A, confirmed the presence of the selected markers 
at the gene expression level in all tumor tissues samples; 
moreover, a complementary or additive expression was 
shown. The strongest positive correlations were observed 
between EpCAM and KRT18, between KRT8 and KRT18, 
and between KRT7 and KRT8. Furthermore, we observed 
a moderate correlation between HER2 and EpCAM, 
and KRT18, respectively. Moderate to weak negative 
correlations were found between MUC1 and EGFR and 
between KRT7 and KRT8 (see Table 1).
OvCa+/CD45– CTCs in protocol B and patient/
tumor characteristics
Finally, in the second part of the study, we processed 
blood samples from 137 patients according to protocol B, 
which combined density gradient centrifugation and multi-
marker immune-fluorescent staining targeting EpCAM, 
EGFR, HER2, MUC1, and cytokeratins. Blood samples 
from both time-points were available from 43 patients, 
whereas just one sample was available in 59 (baseline) 
and in 35 (follow-up) cases, respectively (see Figure 1). 
OvCa+/CD45– CTCs were identified in 27/102 (26.5%) 
baseline blood samples and in 6/78 (7.7%) follow-up 
samples, at a mean count of 12.4 CTCs per ml blood at 
baseline (median 2.5, range < 1–187), and of 2.8 CTCs 
per ml blood in the follow-up samples (median 1, range 
< 1–10) [8]. A detailed description of the positive cases 
including disease stage and CTC counts is given in Table 
3. In none of the ten healthy donor samples OvCa+/CD45– 
cells were observed [Brandt B, Alpers I.,  EUTROC 
European Scientific Meeting 2011, Valencia, Spain].
At baseline, OvCa+/CD45– CTCs were detected 
more frequently at a higher disease stage (FIGO II/III/IV 
p = 0.005), whereas at follow-up these CTCs were more 
likely in patients who were classified as non-responders to 
chemotherapy ( p = 0.015; see Table 2).
The presence of OvCa+/CD45- CTCs at baseline was 
associated with significantly lower levels of KRT5 (mean 
lg2 transformed gene expression 1.12 vs. 0.10, p = 0.040) 
and KRT7 (mean lg2 transformed gene expression 1.34 
vs. 0.36, p = 0.034) gene expression in the corresponding 
tumor tissue samples. To assess whether the gene 
expression in the primary tumor tissue would predict 
the presence of CTCs, we performed a binary logistic 
regression analysis, including disease stage and the 
respective gene expression levels as continuous variables. 
The results indicated that advanced disease and low KRT5 
gene expression were independent predictors of baseline 
CTCs (FIGO: HR 4.410 95% CI 2.926–5.894, p = 0.009; 
87 KRT5: HR 0.697 95% CI 0.336–1.058, p = 0.020).
Due to our tight criteria for CTC positivity, we 
additionally observed “ambiguous” cells, which were 
predominantly double-positive (OvCa+/CD45+), weakly 
stained (OvCa+/–/CD45–), or double-negative (OvCa–/
CD45) with a tumor-like morphology [8]. These 
“ambiguous” cells were found in 16/102 (15.7%) baseline 
and in 9/78 (11.5%) follow-up samples. They were 
more likely in FIGO III than in FIGO IV stage disease 
(p = 0.031), and were mainly observed in chemo-
responders (8/9 cases) [Brandt B, Alpers I., OVCAD 
Meeting 2009, Leuven, Belgium]. 
OvCa+/CD45– CTCs and patient survival
Within the entire cohort of 102 patients with 
baseline blood samples available, the presence of OvCa+/
CD45– CTCs at diagnosis did not have a significant 
impact on survival (OS: HR 1.564, 95% CI 0.923–2.652, 
p = 0.096; PFS: HR 1.167, 95% CI 0.699–1.948, p = 0.555). 
In those 78 patients with a follow-up blood sample 
available, the presence of OvCa+/CD45– CTCs at that 
time-point was associated with worse outcome (OS: HR 
3.305, 95% CI 1.386–7.880, p = 0.007; PFS: HR 5.671, 
95% CI 1.560–20.618, p = 0.008).
OvCa+/CD45– CTCs and minimal residual disease
To investigate the potential role of MRD after 
surgery, we stratified optimally debulked patients (R0) 
by the presence of OvCa+/CD45– CTCs in their baseline 
blood samples. In these patients (n = 69), the presence of 
OvCa+/CD45– CTCs at baseline was significantly associated 
with shorter OS (HR 2.158, 95% CI 1.111–4.191, p = 0.023) 
(see Figure 2), but not with shorter PFS. At the end of 
the total observation period, the majority of these CTC-
positive patients (15/19) had already died, whereas 
about half of the CTC-negative patients (27/50) were 
still alive. According to multivariate analysis, OvCa+/
CD45– CTC-based outcome prediction was independent 
from patient age, FIGO stage, and the presence 
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of peritoneal carcinomatosis (HR 2.720, 95% CI 
1.340–5.522, p = 0.006). 
FISH analysis to confirm and complement CTC 
phenotyping
CGH profiling had been performed as part of a 
preliminary study revealing gains at 3q26.2 and/or at 8q24 
in 65.6% and 57% of the cases, respectively (Figure 3). 
The smallest region of overlap of gain at 3q26.2 
corresponded to the MDS1/EVI1 (MECOM) locus, while 
that at 8q24 corresponded to the HHLA1 (POU5F1) locus 
(Figure 3). BAC clones RP11-250A4 and RP11-240B13 
covering the MECOM and HHLA1 fusion loci were 
subsequently used as probes in FISH experiments in order 
to confirm the presence of cells related to progressive 
disease and possibly to metastasis.
A total of 1500 (RP11-240B13) and 3500 (RP11-
250A4) leukocytes from three and seven healthy donors, 
respectively, were scored for gains of the FISH probes. 
The false-positive hybridization rate (three dots per cell) 
was 0.1% (RP11-250A4) and 0.5% (RP11-240B13), with 
more than 98% of the healthy donor leukocytes showing 
exactly two hybridization dots per cell [8]. In none of these 
Table 1: Correlation between lg2-transformed and normalized gene expression levels of EPCAM, KRT8, KRT18, KRT5, 
KRT7, HER2, MUC1, and EGFR, resulting from microarray analysis of primary tumor tissue samples
EPCAM KRT8 KRT18 KRT5 KRT7 HER2 MUC1 EGFR
EpCAM 1
KRT8 0.370**
KRT18 0.654** 0.760**
KRT5 - 0.335** 0.204*
KRT7 - 0.635** 0.279** 0.353**
HER2 0.441** - 0.351** - -
MUC1 0.372** –0.240* - - –0.510** 0.468**
EGFR - –0.284** - - –0.286** 0.314** 0.355** 1
Pearson’ correlation coefficients are given, *correlation significant at the 0.05 level, **correlation significant at the 0.01 level, 
- correlation not significant.
Figure 1: Flow diagram depicting the sample processing according to protocol A and B, including basic results.
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leukocytes we detected more than three dots. Thus, we 
determined a cut-off value of at least three hybridization 
spots per cell to confirm that this cell was a tumor cell [8].
For FISH analysis of ovarian cancer CTCs, nine 
patients with more than two OvCa+/CD45– CTCs per 
ml blood with three of them having “ambiguous” cells 
were selected. We found cells with MECOM and/or 
HHLA1 gains in all of the investigated blood samples 
(Table 4). Likewise, the detection of chromosomal gains 
complemented CTC phenotyping in those cases showing 
“ambiguous” double-negative cells (OvCa–/CD45–) with  a 
tumor-like morphology and weakly stained cells (OvCa+/–/
CD45–).
MECOM and/or HHLA1 gains are associated 
with metastatic spread
In addition to the observation that all patients with 
primary metastasis (stage FIGO IV) presented with 
MECOM and/or HHLA1 positive CTCs, a phenotypical 
characterization of the OvCa+/CD45– CTCs observed in 
a particular patient was performed. The baseline blood 
Table 2: The presence of CTCs and their association to clinico-pathologic characteristics of the patients
Baseline blood samples Follow-up blood samples
N CTC+ (%) CTC– (%) p N CTC+ (%) CTC– (%) p
Total cases 102 27 (26.5) 75 (73.5) 78 6 (7.7) 72(92.3)
Median age, yrs (SD) 56. 0 (±10.4) 60.0 (±11.7) 0.268 62.0 (±7.7) 57.0 (±11.8) 0.279
FIGO stage
 II
 III 
 IV 
4
67
31
0 (0.0)
12 (17.9)
15 (48.4)
4 (100.0)
55 (82.1)
16 (51.6)
0.005
2
62
14
0 (0.0)
4 (6.5)
2 (14.3)
2 (100.0)
58 (93.5)
12 (85.7)
0.408
Histology
Serous
Non-serous
86
16
22 (25.6)
5 (31.3)
64 (74.4)
11 (68.7)
0.758
71
7
5 (7.1)
1 (14.3)
66 (92.9)
6 (85.7)
0.442
Grade
 G1 or G2
 G3
21
81
6 (28.6)
21 (25.9)
15 (71.4)
60 (74.1)
0.807
17
61
2 (11.8)
4 (6.6)
15 (88.2)
57 (93.4)
0.606
Response to therapy
 yes
 no
72
29
20 (27.8)
7 (24.1)
52 (72.2)
22 (75.9)
0.708
61
16
2 (3.3)
4 (25.0)
59 (96.7)
12 (75.0)
0.015
Neo-adjuvant  CT
 yes
 no
17
85
7 (41.2)
20 (23.5)
10 (58.8)
65 (76.5)
0.116
10
68
2 (20.0)
4 (5.9)
8 (80.0)
64 (94.1)
0.168
Residual disease
 yes 
 no 
33
69
8 (24.2)
19 (27.5)
25 (75.8)
50 (72.5)
0.724
29
49
4 (13.8)
2 (4.1)
25 (86.2)
47 (95.4)
0.188
Peritoneal carcinosis
 yes 
 no 
67
26
20 (29.9)
4 (15.4)
47 (70.1)
22 (84.6)
0.152
49
21
6 (12.2)
0 (0.0)
43 (87.8)
21 (100.0)
0.313
Ascites
 yes 
 no 
67
26
20 (29.9)
4 (15.4)
47 (70.1)
22 (84.6)
0.152
54
16
5 (9.3)
0 (0.0)
49 (90.7)
16 (100.0)
0.582
CA-125
 <35 U/ml
 ≥35 U/ml
7
82
3 (42.9)
20 (24.4)
4 (57.1)
62 (75.6)
0.369
26
39
4 (15.4)
1 (2.6)
22 (84.6)
38 (97.4)
0.148
HE-4
 <290 pM
 ≥291 pM
42
51
12 (28.6)
12 (23.5)
30 (71.4)
39 (76.5)
0.580
n.a.
Cytospin samples from density gradient enriched blood samples taken at diagnosis and six months after completion of 
first-line chemotherapy were evaluated for the presence of CTCs (OvCa+/CD45– cells) using protocol B. Samples with 
“ambiguous” staining results were considered to be CTC-negative, unless chromosomal gain was detected by FISH 
analysis. n.a.: not assessed.
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Figure 3: Copy Number Alterations (CNA)  in 128 sporadic ovarian carcinomas and mapping of shortest regions 
of overlap (SRO) for gains at 3q26 and 8q24. (A) represents a whole genome CNA profile (gains blue, losses red). Regions at 
3q26.2 and 8q24 were the most frequently gained (65.6 and 57% of the cases respectively). To select BAC best adapted BAC clones 
for FISH experiments, SROs were mapped (B and C) corresponding to blow up boxes showing profiles of all the tumors gained in 
the analyzed regions). BAC clones selected were RP11-250A4, at 3q26.2 covering the MECOM locus, and RP11-240B13, at 8q24 
encompassing the HHLA1 gene.
 Figure 2: Overall survival of optimally debulked ovarian cancer patients. The patients are stratified by presence (black line) 
or absence (grey line) of OvCa+/CD45– CTCs at diagnosis. All patients (n = 69) received primary surgery without any macroscopically 
visible tumor residue left. Differences in survival were compared using the log-rank test. 
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sample of that patient (H071) was the one with the highest 
number of CTCs (187 OvCa+/CD45– cells per ml blood; see 
Table 3). These OvCa+/CD45– cells were CK7/18-positive, 
with just 10% being EpCAM-positive, albeit at much 
lower staining intensity [8]. That difference of intensity 
was observed in metastases located in the spleen and liver 
as well, suggesting higher CK7/18 than EpCAM protein 
expression in these samples. In contrast, CKs and EpCAM 
were detected at similar levels in the primary tumor tissue. 
At the genome level, gains in the MECOM and HHLA1 loci 
Table 3: Characteristics of CTC-positive patients
Patient ID Disease stage PFS (months) OS (months)
OvCa+/CD45– cells per ml blood
baseline follow-up
H071 IV (liver, spleen) 16 58 187 n.a.
B151 IV (lung) 65 65 20 n.a.
B132 IV (LN) 14 45 11 n.a.
B159 IV (liver) 12 27 9 10
H076 IV (inguinal LN) cPD 9 5 n.a.
B117 IV (inguinal LN) 13 37 4 n.a.
H079 IV (liver, LN) § 14 4 n.a.
V046 IV (spleen) 12 44 3 n.a.
B131 IV (liver) 25 48 2 n.a.
B137 IV (inguinal LN) 70 70 2 0
B175 IV (inguinal LN) 8 14 2 n.a.
L177 IV (spleen) 11 35 2 0
B126 IV (PE) 15 28 1 0
H083 IV (spleen) § 10 1 0
B171 IV (inguinal LN) 12 34 0 3
B111* IV (PE) 22 44 0 n.a.
B120 IIIC 9 21 28 n.a.
V047 IIIC 10 36 14 n.a.
B135 IIIC cPD 4 12 n.a.
B157 IIIC 44 44 4 n.a.
B146 IIIC 31 34 3 n.a.
B144 IIIC 21 37 1 n.a.
H073 IIIC 36 53 1 n.a.
H082 IIIC 32 53 < 1 n.a.
I020 IIIC 12 18 < 1 n.a.
L220 IIIC 15 56 1 0
V035 IIIC 13 69 0 1
L083 IIIC 11 25 n.a. 1
L141 IIIC 8 9 0 < 1
L227 IIIC 11 20 n.a. < 1
B129 IIIA 21 39 2 n.a.
B168 IIIA 14 67 11 n.a.
31 patients were scored as CTC-positive due to the presence of OvCa+/CD45– cells in their baseline and/or follow-up blood 
sample (protocol B). The stage of the disease at diagnosis according to the FIGO classification is given (site of distant 
metastases in brackets). 
*One further patient (B111) was scored as CTC-positive due to chromosomal gain in 8q24.
n.a.: blood sample not available; cPD: clinical progressive disease at completion of adjuvant treatment; §: date of recurrence 
not assessed; LN lymph node; PE malignant pleural effusion.
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were observed in the primary tumor and the metastases, as 
well as in just 25% and 50% of the CK7/18-positive CTCs, 
respectively. In addition, chromosomal gains were found in 
CK-negative cells which would not have been identified as 
tumor cells by immune-fluorescent staining alone.
DISCUSSION 
In the present study we developed a workflow for 
the detection and characterization of CTCs in ovarian 
cancer blood samples. The low number of CTC-positive 
samples observed in protocol A and in comparable studies 
employing epithelial markers alone [9, 10] led us to modify 
the protocol accordingly. Being aware of the heterogeneity 
of the CTC population, we assumed that a multi-marker 
approach might be more successful in ovarian cancer as 
well. We thereupon chose multiple targets, namely EpCAM, 
CKs, EGFR, HER2, and MUC1 for the immune-fluorescent 
detection of CTCs in the remaining blood samples (protocol 
B), and the analysis of chromosomal gains in MECOM/
HHLA1 loci as a complementary approach. Although our 
study may have some limitations, our approach led us to the 
key observation that an unfavorable prognosis of optimally 
debulked patients was associated with the presence of CTCs 
before surgery. This finding indicates that CTCs may serve 
as biomarkers for MRD in ovarian cancer, and that they 
could therefore have the potential to become a decisive 
factor in the clinical management of ovarian cancer patients.
In view of the low number of CTC-positive 
samples in protocol A (just 5/139 baseline samples and 
none of the 56 follow-up samples contained CK+/CD45– 
cells), we then used protocol B in the further course of 
the study, which comprised markers associated with 
epithelial characteristics (EpCAM, CK8/18) as well 
as with metastatic progression (MUC1, EGFR, CK5/7 
and HER2 [11–13]) in order to catch various subsets of 
CTCs displaying different phenotypes. Furthermore, 
we combined antibodies from several sources to detect 
diverse epitope subsets [14]. In addition to the whole 
genome expression data from the OVCAD study cohort 
(data not shown), previously published studies employing 
the AdnaTest (Qiagen) indicated that MUC1, HER2, and 
EGFR could be suitable to complement epithelial markers. 
The AdnaTest is based on the immune-magnetic isolation 
of ovarian cancer CTCs using antibodies against MUC1 
and EpCAM. On the molecular level, the majority of 
those CTCs were characterized by MUC1 and HER2 gene 
expression [15, 16].
In regard to the rareness and the heterogeneity 
of CTCs in ovarian cancer [17], we performed a density 
gradient centrifugation-based enrichment of up to 20 ml 
of blood as the very first step in both protocol A and B. 
Thereby we were able to analyze more than twice as much 
blood as other investigators using immune-magnetic bead-
based techniques to enrich CTCs, such as the CellSearch 
assay (Janssen Diagnostic, USA) and the AdnaTest 
(Qiagen), which start from a 7.5 ml and 5.0 ml blood 
sample, respectively. The mean recovery rate of the above 
mentioned density gradient centrifugation was 76.6% for 
spiked-in ovarian cancer cells (data not shown), which is 
slightly lower than with prostate [18] or breast cancer cells 
[19]; nevertheless in our hands the same type of enrichment 
had already been proven to be effective for ovarian cancer 
and subsequent detection of CTC-related transcripts [20]. 
We observed noticeable more CTC-positive cases 
after switching from protocol A to B. By using multiple 
markers for the immune-fluorescent detection of CTCs, 
the numbers of positive cases increased from 5/139 (3.6%) 
to 27/102 (26.5%) at baseline, and from 0/56 (0%) to 
6/78 (7.7%) at follow-up. In line with other studies, the 
presence of OvCa+/CD45– CTCs in the protocol B samples 
significantly correlated with disease stage and therapy 
response [21–24].
However, the positivity rates obtained with 
protocol A and B may not be directly compared, because 
the respective blood samples differ in terms of patient 
Table 4: Characteristics of FISH-positive patients
Patient FIGO OvCa+/CD45– cells/ml blood CNV (gains) Time-point
H071 IV (liver, spleen) 187 MECOM/HHLA1 baseline
B120 IIIC 28 MECOM baseline
B151 IV (lung) 20 MECOM/HHLA1 baseline
V047 IIIC 14 MECOM/HHLA1 baseline
B146 IIIC 3 MECOM baseline
B175 IV (PE) 2 MECOM baseline
L177 IV (spleen) 2 MECOM baseline
B111* IV (PE) 0 HHLA1 baseline
B159 IV (liver 10 MECOM follow-up
Nine patients were selected for FISH analysis due to the presence of at least two OvCa+/CD45– cells per ml blood.
*One further patient (B111) was scored as CTC-positive due to chromosomal gain in 8q24.
CNV copy number variation; PE pleural malignant effusion.
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characteristics, like disease stage and tumor grade. Thus 
the divergent results obtained with protocol A and B 
may only be partially attributed to the methodological 
differences of the respective protocols.
Interestingly, we observed that the presence of 
OvCa+/CD45– CTCs detected in protocol B was associated 
with low KRT5 and KRT7 gene expression levels in the 
paired primary tumor tissue samples. Pan-cytokeratin 
antibodies are widely used for immune-histochemical 
staining of CK-positive tumor cells; however, there is 
sparse information available on cytokeratin phenotyping. 
Among the few studies investigating the role of CK5 
protein in ovarian cancer, various rates of CK5-positive 
tumor tissue samples, ranging from 25% to 68%, are 
reported [25, 26]. Another study evaluating cytokeratins 
as biomarker to discriminate primary from metastatic 
adenocarcinoma found that CK7 protein expression is 
reduced in metastatic ovarian cancer [27]. Developing 
a gene expression profile that may predict the presence 
of CTCs–in line with Molloy’s study in breast cancer 
[28]–was out of the scope of the present study, but may 
eventually be subject of further investigations.
Studies investigating CTCs in ovarian cancer 
published to date vary markedly with regard to patient 
population, timing of blood draw, and length of follow-
up. Furthermore, the methods for processing the blood 
samples and the decisive criteria for CTC-positivity vary 
greatly. For this reason any comparison of the results may 
only be carried out with caution. However, our results 
clearly support the notion of other authors that CTCs are 
present in the blood of ovarian cancer patients and that 
they may have clinical relevance (reviewed by [6]), and 
that in ovarian cancer a more comprehensive approach that 
does not rely on the detection of epithelial markers alone 
may be needed [20, 29–31]. 
The present results confirm the findings from our 
earlier study, which employed a combination of density 
gradient-based enrichment and detection of CTC–related 
gene markers using qPCR [20]. In both studies we 
demonstrated the prognostic impact of CTCs after 
chemotherapy; however, due to the limited sample number 
in the present study we were not able to assess whether 
that impact was independent from other known prognostic 
factors, and whether these CTCs may predict MRD 
in patients with clinical complete remission following 
treatment.
Our observation that the presence of baseline 
CTCs is associated with worse outcome in a sub-group 
of optimally debulked patients is in line with the findings 
of Pearl et al., who used a cell adhesion matrix-based, 
functional cell enrichment platform to isolate invasive 
CTCs [24]. Like our approach to enrich CTCs by density 
gradient centrifugation, that platform may be regarded as 
being independent from epithelial markers; however the 
results obtained from the study mentioned above differ 
from those of our study in terms of median numbers 
of CTCs in ovarian cancer patients (i.e. 42 per ml vs. 
2.8 per ml), and in terms of CTC presence in healthy 
and benign donors, which was observed at a rate of 5% 
in the Pearl study. These differences indicate that in our 
study some samples may be false negative. The presence 
of “ambiguous” double-negative cells further supports 
that assumption. We observed these “ambiguous” cells in 
16% of the baseline and in 12% of the follow-up samples. 
In particular the OvCa–/CD45– cells were discovered by 
chance, and it was out of the scope of our study to screen 
all samples for morphologically atypical and entirely 
unstained cells. A possible explanation for the decrease 
or even absence of a specific staining may be a reduced 
protein expression of the chosen markers or a proteolytic 
cleavage of their extracellular domains, both phenomena 
to occur during cancer progression [32–34]. Inconsistent 
results regarding CTC positivity rate and their prognostic 
relevance in earlier studies employing EpCAM-based 
systems may be at least partially due to the heterogeneity 
of the CTC population [35–37].
The presence of “ambiguous” cells demanded for 
an additional approach to ascertain whether these cells 
were cancer cells or not. Therefore, we analyzed the 
chromosomal aberrations in loci 3q26 and 8q24 using 
FISH probes for the survival and stem cell-like fusion 
genes MECOM and HHLA1. In concordance with 
earlier studies [38–40] we observed MECOM copy 
number gains in more than two thirds of the primary 
tumors of ovarian cancer patients. Likewise, it has 
been demonstrated that aberrations in the chromosomal 
region 8q24.21-8q24.22 comprising the HHLA1 locus 
occurred frequently in these cancers [41]. The presence 
of MECOM and/or HHLA1 gains in all CTC samples 
investigated confirmed the specificity of the multi-
marker staining, and furthermore allowed us to ascertain 
that “ambiguous” cells corresponded to cancer cells, 
thus enabling us to extend the CTC count. In addition, 
we observed that even in patients with clearly assigned 
CTCs (OvCa+/CD45– cells), a side population of 
unstained OvCa–/CD45– cells harboring chromosomal 
gains was detected by FISH. Thus, in many ovarian 
cancer patients not only the actual number of CTCs but 
also their prevalence might be higher than assumed. 
The analysis of CTCs in patient H071 further revealed 
that these cells were heterogeneous not only regarding 
protein expression, but also at the genome level.
In conclusion, this study shows the prognostic 
impact of CTCs on the outcome of ovarian cancer 
patients included into the OVCAD study cohort. Our 
findings indicate that these CTCs could serve as surrogate 
markers for minimal residual disease beyond complete 
resection of the tumor. Future investigations using 
scanning microscopy or molecular probes may be useful 
in validating our preliminary findings in larger patient 
cohorts in order to strengthen the role of CTC diagnostics 
in the future management of ovarian cancer patients.
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MATERIALS AND METHODS
Patients
The patients with histopathologically confirmed 
primary epithelial ovarian cancer were part of the 
prospective multi-center OVCAD study cohort. The 
overall goal of that study was to investigate new 
predictors for the early detection of MRD in epithelial 
ovarian cancer. Detailed inclusion and exclusion criteria, 
together with clinical data have already been presented 
elsewhere [42]. All patients received standard treatment 
consisting of debulking surgery and platinum-based 
adjuvant chemotherapy. Response to treatment was 
evaluated by experienced gynecological oncologists of 
the participating university centers according to the WHO 
criteria, i.e. by an increase in the nadir serum CA-125 
level according to the GCIG criteria and by radiological 
(clinical) confirmation [43]. Patients were classified 
as non-responder if progression was diagnosed during 
treatment or recurrence occurred within six months after 
end of first-line chemotherapy. Written informed consent 
was obtained from each patient before study inclusion. 
The study protocol was approved by the local ethics 
committees of the participating OVCAD partners. 
Blood samples and CTC enrichment
Twenty ml of peripheral blood was taken by 
venipuncture at primary diagnosis (prior to treatment; i.e. 
baseline samples), and six months after completion of the 
adjuvant platinum-based chemotherapy (i.e. follow-up 
samples). The blood was collected into Vacuette EDTA 
tubes (Greiner Bio-One). A two-layer density gradient 
centrifugation to obtain a CTC enriched cell fraction and a 
plasma layer was performed as described previously [20]. 
Initially, the density gradient enriched cells were further 
processed employing protocol A, which finally was replaced 
by protocol B in the course of the study (see Figure 1). 
CA-125 and HE-4 levels were assessed in the top plasma 
layer obtained after density gradient centrifugation, using 
the Milliplex MAP Human Cancer Biomarker Panel Kit 
(Millipore) and HE-4 EIA assay (Fujirebio Diagnostics AB).
CTC detection in protocol A
Following density gradient centrifugation as 
described above, the CTC containing cell fraction 
was further enriched for EpCAM-positive cells using 
the CellSearch Profile Kit as described by Alpers [7]. 
Then, each two cytospins were prepared (Hettich 
Rotofix 20 cytocentrifuge, 160x g, and 3 min), which 
were subsequently stained using fluorescently labelled 
antibodies to CK7/18 (clone A45-BB3, Micromet) 
and CK5/8 (clone C22, Progen). Leukocytes were 
counterstained using an Alexa Fluor 488 labelled antibody 
to hematopoetic lineage-specific CD45 (clone H130, 
Biolegend). Nuclei were visualized using DAPI (Carl 
Roth). CTCs were identified as CK+/CD45– cells.
Selection of CTC markers for protocol B 
In light of the unexpected results obtained from 
samples which had been processed using protocol A in the 
initial phase of the study, we targeted EGFR, HER2, and 
MUC1 in addition to EpCAM and CK for the immune-
fluorescent staining of CTCs in protocol B. These targets 
are known to be associated with cell differentiation, 
proliferation, tumor promotion and metastasis [11–
13], and have already proven their suitability for CTC 
characterization [15, 16, 37]. Furthermore, microarray 
data from primary tumor tissue samples collected from the 
OVCAD cohort were available to verify the presence of 
these additional markers at the gene expression level [44]. 
CTC detection in protocol B
After the enrichment by density gradient 
centrifugation, each three cytospins were prepared by 
applying a total number of 2 × 105 enriched cells onto 
glass slides as described above. These samples were 
stained using a cocktail of primary murine antibodies 
to CK7/18 (clone A45-BB3, Micromet), CK5/8 (clone 
C22, Progen), EpCAM (clone Ber-EP4, Dako; clone 
VU-ID9, Novocastra), MUC1 (clone E29, Dako), EGFR 
(clone sc-120, Santa Cruz), and HER2 (clone NCL-CB11, 
Novocastra) as described by Alpers [7]. The appropriate 
dilution of each antibody to ensure high specificity was 
established using cell lines (MDA-MB-468, SK-OV3, 
MCF-7) and healthy donor leukocytes. Specific binding of 
the primaries was detected using a biotinylated secondary 
antibody (rabbit anti-mouse, Dako) and Alexa Fluor 594 
labelled streptavidin (Invitrogen). Leukocytes and nuclei 
were visualized as described above. The specificity of 
multi-marker staining was assessed in the density gradient-
enriched cell fraction of ten healthy donors. Unequivocal 
identification of CTCs (named further OvCa+/CD45−) in 
patients’ samples was allowed due to a strong Alexa Fluor 
594 signal (OvCa+), the absence of leukocyte-specific 
staining (CD45−), and to the presence of an intact nucleus 
and cell morphology. 
BAC-based CGH analysis of tumor DNA
Comparative genomic hybridization (CGH) was 
performed on tumor DNA from 128 ovarian cancer 
patients, which was analyzed on two generations of 
BAC-arrays (Integragen) IgV6+ (5015 BACs), IgV7 
(5878 BACs), with a median resolution of 0.6 Mb. 
BACs (bacterial artificial chromosomes) were spotted in 
quadruplicates. DNA labeling and hybridization were done 
as previously described [45] with slight modifications: 
600 ng DNA were labeled with the BioPrime Total 
Genomic Labeling System (Invitrogen). Arrays were 
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scanned using an Axon 4000B scanner (Molecular 
Devices), and images were analyzed using Genepix 6.0. 
Data were analyzed in a web-based platform for copy 
number array management and analysis (http://bioinfo-
out.curie.fr/CAPweb/). Normalized and replicates-filtered 
data were exported as text file for further analyses. In 
order to analyze all the data from different Integrachip 
versions, we used the Nexus 6.0 Software (Biodiscovery). 
Analysis settings for data segmentation and calling were 
the following: significant threshold for Rank Segmentation 
algorithm: 0.005, Max Continuous Probe Spacing: 6000, 
Min number of probes per segment: 6, high level gain: 
0.485, gain, 0.138, loss:−0.153, homozygous copy 
loss:−0.73. Nexus 6.0 Software was used to calculate 
frequency plots, factor enrichment (significantly over-
represented factor values in a particular factor group 
identified using the two-tailed Fisher’s Exact test at a 
p-value of p < 0.05), significant chromosomal differences 
between two groups (two-tailed Fisher’s exact test with 
p-value < 0.005 and minimal frequency difference set 
at 10%) and Survival Predictive Power (log-rank test is 
used to identify genomic regions yielding a high degree of 
survival prediction;  p-value was calculated by permuting 
the survival time for each sample and comparing the log-
rank statistic for the permuted data to the original data; 
threshold used was p-value < 0.05).
FISH on CTCs and primary tumor/metastasis 
tissues
The protocol was established as part of the doctoral 
thesis of Iris Alpers [8]. FISH probes were prepared from 
DNA isolated from BAC clones RP11-250A4 (3q26, 
MDS1 and EVI1 complex locus protein EVI1 (MECOM)) 
and RP11-240B13 (8q24, HERV-H LTR-associated 
1  (HHLA1)) using the Large DNA Construct Isolation 
Kit (Qiagen) and the BioPrime Total Genomic Labeling 
System (Invitrogen) according to the manufacturers’ 
protocols. De-paraffinized FFPE sections and cytospin 
samples were processed as described previously [46] using 
1 µl COT1 Human DNA (Roche), 1 μL of CEP7 Spectrum 
Aqua (Abbott Molecular) as a reference probe, and 2 μL of 
Spectrum Orange - labeled probe (Abbott Molecular) for 
chromosomal region 3q26 or 8q24 suspended in 6 μL of 
hybridization buffer. For each tissue specimen, target and 
reference probe signals were counted in 100 cells showing 
a minimum of two signals for the reference probe. DNA 
gain and loss were defined as the ratio of the number of 
target probe signal over reference probe signals being ≥1.5 
or ≤0.75, respectively. For FISH on CTCs, the immune-
staining protocol was slightly modified (streptavidin 
labelled with Alexa Fluor 488), and counterstaining of 
leukocytes was omitted. Leukocytes from healthy donors 
were scored for gains of the probes to obtain an estimate 
of the false-positive hybridization rate. 
Statistical analysis
The Pearson’s chi-square and Fisher’s exact test 
were used to assess the relationship between CTC 
presence and clinico-pathological characteristics of the 
patients. Clinical endpoints were calculated as follows: 
progression-free survival (PFS), between time of blood 
draw (baseline: prior to surgery, follow-up: six months 
after completion of adjuvant chemotherapy) and first 
recurrence; overall survival (OS), between time of blood 
draw (see above) and death due to any cause. Kaplan-
Meier survival analyses and log-rank testing were used 
to compare survival outcomes [47]. Cox proportional 
hazards regression was used to determine univariate and 
multiple hazards ratios [48]. Covariates included were 
patient age as continuous variable, and FIGO stage (II/
III vs. IV), residual tumor mass after surgery (R0 vs. 
R > 0), peritoneal carcinomatosis (absence vs. presence), 
and the CTC status (OvCa+/CD45– absence vs. presence) 
as dichotomous variables. The model was built using a 
forward stepwise method by entering all variables at a 
p value of less than 0.05 and removing them at a p value 
of greater than 0.10. Statistical analysis was performed by 
SPSS version 19.0 (SPSS Inc., Chicago, IL). The level of 
significance was set at p < 0.05. 
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